Skip to main content
SpringerLink
Log in

Lisuride Pharmacology and Treatment of Parkinson’s Disease

  • Chapter
Drugs for the Treatment of Parkinson’s Disease

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 88))

Abstract

Lisuride hydrogen maleate [1,1 diethyl-3-(9,10-didehydro-6-methyl-8α-ergolinyl] urea is the first derivative of isolysergic acid in clinical use. It is an 8-α-aminoergoline and was synthesized by Zikan and Semonsky (1968). It is a white slightly bitter tasting substance, which is reasonably stable at room temperature if not exposed to light. Lisuride hydrogen maleate is soluble in water or saline up to 1 mg/ml. Owing to its low effective dose, it is therefore the first dopamine agonist which can also be used on a parenteral basis (Dorow et al. 1980).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Adams LM, Geyer MA (1985) Patterns of exploration in rats distinguishes lisuride from lysergic acid diethylamide. Pharmacol Biochem Behav 23: 461–468

    Article  PubMed  CAS  Google Scholar 

  • Agnoli A, Ruggieri S, Baldassarre M, Stocchi F, Denaro A, Falaschi P (1983) Dopaminergic ergots in Parkinsonism. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds). Lisuride and other dopamine agonists. Raven, New York, pp 407–417

    Google Scholar 

  • Ahlenius S, Larsson K, Svensson L (1980) Stimulating effects of lisuride on masculine sexual behaviour. Eur J Pharmacol 64: 47–51

    Article  PubMed  CAS  Google Scholar 

  • Aizawa T, Kutsuzawa T, Otomo E, Goto F, Tazaki Y, Abe H, Omae T, Kameyama M, Ito H (1980) Clinical utility of eunal in treatment of cerberovascular disorders: multi-center double-blind study in comparison with dihydroergotoxine mesylate. Clin Eval 8: 577–628

    Google Scholar 

  • Albizzati MG, Alemani A, Bassi G, Ferrarese C, Frattola L, Trabucchi M (1982) Effetti del lisuride nella patologia discinetico distonica: Considerazioni patogenetiche. In: Agnoli A, Bertolani G (eds) Morbo di Parkinson e compromissione delle attivita’ nervose superiori. 8th Meeting LIMPE, Rome, 31 Oct 1981. Guanelli, Rome, pp 223–231

    Google Scholar 

  • Azuma H, Oshino N (1980) Stimulatory action of lisuride on dopamine-sensitive adenylate cyclase in the rat striatal homogenate. Jpn J Pharmacol 30: 629–639

    Article  PubMed  CAS  Google Scholar 

  • Azuma H, Miyazawa T, Ishikawa T, Oshino N (1982) Effects of an ergot derivative lisuride, on the central nervous system. Stimulatory effect on local cerebral glucose utilization in the rat Folia Pharmacol Jpn 80: 69–81

    CAS  Google Scholar 

  • Battaglia G, Titeler M (1981) Direct binding of [3H] lisuride to adrenergic and serotonergic receptors. Life Sci 29: 909–916

    Article  PubMed  CAS  Google Scholar 

  • Bergstrom DA, Bromley SD, Walters JR (1984) Dopamine agonists increase pallidal unit activity: attenuation by agonist pretreatment and anesthesia. Eur J Pharmacol 100: 3–12

    Article  PubMed  CAS  Google Scholar 

  • Besser GM, Wass JAH, Grossmann A, Moult PJA, Bouloux P (1983) Hormonal and clinical effects of dopamine agonists In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 239–254

    Google Scholar 

  • Birkmayer W, Riederer P (1983) Effects of lisuride on motor function, psychomotor activity, and psychic bahaviour in Parkinson’s disease. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 453–461

    Google Scholar 

  • Bittkau S, Przuntek H (1986) Psychosis and the lisuride pump. Lancet 11:349 (letter)

    Google Scholar 

  • Bohnet HG, Hanker JP, Horowski R, Wickings EJ, Schneider HPG (1979) Suppression of prolactin secretion by lisuride throughout the menstrual cycle and in hyperprolactinaemic menstrual disorders. Acta Endocrinol. 92: 8–19

    PubMed  CAS  Google Scholar 

  • Bohnet HG, Hilland U, Hanker JP, Schneider HPG (1981) Hormonelle Diagnostik und Therapie der Mastodynie. Wissenschaftl Information 7: 87–94

    Google Scholar 

  • Bosio A, Bassi S, Govoni S, Spano PF, Trabucchi M, Covelli V, Frattola L (1984) Lisuride in extrapyramidal disorders: a possible mechanism of action. In: Hassler RG, Christ JF (eds) Advances in neurology vol 40. Raven, New York, pp 523–526

    Google Scholar 

  • Bracco F, Meneghetti G, Feria S, Giometto B, Battistin L (1984) Effetti della lisuride nel trattamento del morbo di Parkinson. Osservazioni preliminari. In: Agnoli A, Bertolani G (eds) LIMPE Atti della 10. Reunione,Disorderi autonomici e correlati neuroendocrini delle malattie extrapiramidali’. Guanella, Rome, pp 272–278

    Google Scholar 

  • Bräutigam M, Flosbach CW, Herken H (1980) Depression of reserpine-induced muscular rigidity in rats after administration of lisuride into the spinal subarachnoid space. Naunyn-Schmiedeberg’s Arch Pharmacol 315: 177–179

    Article  Google Scholar 

  • Brazenor RM, Angus JA (1982) Actions of serotonin antagonists on dog coronary artery. Eur J Pharmacol 81: 569–576

    Article  PubMed  CAS  Google Scholar 

  • Brinkmann A, Schumm F, Dichgans J (1985) Therapie des Meige-Syndroms. In: Gänshirt H, Berlit P (eds) Kardiovaskuläre Erkrankungen und Nervensystem, Neu- rotoxikologie, Probleme des Hirntodes. Springer, Berlin Heidelberg New York, pp 662–665

    Google Scholar 

  • Burdman JA, Calabrese MT, Harcus CT, MacLeod RM (1982) Lisuride, a dopamine agonist, inhibits DNA synthesis in the pituitary gland. Neuroendocrinology 35: 282–286

    Article  PubMed  CAS  Google Scholar 

  • Burns RS, Calne DB (1981) Treatment of parkinsonism with artificial dopaminomimetics; pharmacokinetic considerations. In: Corsini GU, Gessa GL (eds) Apomorphine and other dopaminomimetics, vol 2. Raven, New York, pp 93–106

    Google Scholar 

  • Burns, RS, Gopinathan G, Hümpel M, Dorow R, Calne DB (1984) Disposition of oral lisuride in Parkinson’s disease. Clin Pharmacol Ther 35: 548–556

    Article  PubMed  CAS  Google Scholar 

  • Camerlingo M, Bottacchi E, D’Alessandro G, Gambaro P, Crippa D, Finelli F, Mamoli A (1986) Un anno di esperienza con ergot-derivati nel trattamento di monoterapia di pazienti Parkinsoniani di prima diagnosi. In: Agnoli A, Battistin L (eds) L.I.M.P.E., Atti della 12. Riunione,Morbo di Parkinson: le nuove terapie’. Guanella, Rome, 1986, pp 188–196

    Google Scholar 

  • Cangi F, Fanciullacci M, Pietrini U, Boccuni M, Sicuteri F (1985) Emergence of pain and extra-pain phenomena from dopaminomimetics in migraine. In: Pfaffenrath V, Lundberg PO, Sjaastad O (eds) Updating in headache. Springer, Berlin Heidelberg New York, pp 276–280

    Google Scholar 

  • Caraceni T, Giovannini P, Parati E, Scigliano G, Grassi MP, Carella F (1984) Bromocriptine and lisuride in Parkinson’s disease. In: Hassler RG, Christ JF (eds) Advances in neurology, vol 40. Raven, New York, pp 531–535

    Google Scholar 

  • Carruba MO, Mantegazza P (1983) Behavioural pharmacology of ergot derivatives. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 65–77

    Google Scholar 

  • Carruba MO, Ricciardi S, Negreanu J, Calogero M, Mantegazza P (1980) Effects of lisuride on body temperature of rats and rabbits: relation to microsomal biotransformation and dopaminergic receptor stimulation. Psychopharmacology 70: 223–229

    Article  PubMed  CAS  Google Scholar 

  • Carruba MO, Ferrari P, Rossi AC, Mantegazza P (1983) Effects of antihypertensive drugs on sexual behaviour of male rats. Pharmacol Res Commun 15: 367–375

    Article  PubMed  CAS  Google Scholar 

  • Carruba MO, Ricciardi S, Chiesara E, Spano PF, Mantegazza P (1985) Tolerance to some behavioural effects of lisuride, a dopamine receptor agonist, and reverse tolerance to others, after repeated administration. Neuropharmacology 24: 199–206

    Article  PubMed  CAS  Google Scholar 

  • Carstensen M, Söhnchen R, Braendle W, Bettendorf G (1983) Effects of prolactin-lowering agents in the treatment of disorders of fertility. In: Calne DB, Harowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 337–343

    Google Scholar 

  • Carvey PM, Klawans HL (1983) Effect of chronic lisuride treatment on stereotypical and myoclonic jumping behavior in guinea pigs. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 97–107

    Google Scholar 

  • Chiodini PG, Liuzzi A, Silvestrini F, Verde G, Cozzi R, Marsili MT, Horowski R, Passerini F, Luccarelli G, Borghi PG (1978) Size reduction of a prolactin secreting adenoma during a long-term treatment with a dopamine-agonist: (lisuride). Int Symp on Pituitary Microadenomas, Milan (abstract )

    Google Scholar 

  • Chiodini PG, Liuzzi A, Verde G, Cozzi R, Silvestrini F, Marsili MT, Horowski R, Passerini F, Luccarelli G, Borghi PG (1980) Size reduction of a prolactin secreting adenoma during long-term treatment with the dopamine agonist lisuride. Clin Endocrinol 12: 47–51

    Article  CAS  Google Scholar 

  • Chiodini P, Liuzzi A, Cozzi R, Verde G, Oppizzi G, Dallabonzana D, Spelta B, Silvestrini F, Borghi G, Luccarelli G, Rainer E, Horowski R (1981) Size reduction of macroprolactinomas by bromocriptine or lisuride treatment. J Clin Endocrinol Metab 53: 737–743

    Article  PubMed  CAS  Google Scholar 

  • Cote T, Munemura M, Kebabian J (1979) Lisuride hydrogen maleate: an ergoline with beta-adrenergic antagonist activity. Eur J Pharmacol 59: 303–306

    Article  PubMed  CAS  Google Scholar 

  • Cote TE, Eskay RL, Frey EA, Grewe CW, Munemura M, Tsuruta K, Brown EM, Kebabian JW (1983) Actions of lisuride on adrenoceptors and dopamine receptors. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 45–53

    Google Scholar 

  • Critchley P, Grandas Perez F, Quinn N, Coleman R, Parkes D, Marsden CD (1986) Psychosis and the lisuride pump. Lancet II:349 (letter)

    Article  Google Scholar 

  • Cronin MJ, Valdenegro CA, Perkins SN, MacLeod RM (1981) The 7315 a pituitary tumor is refractory to dopaminergic inhibition of prolactin release but contains dopamine receptors. Endocrinology 109: 2160–2166

    Article  PubMed  CAS  Google Scholar 

  • Crosignani PG, Ferrari C, Liuzzi A, Benco R, Mattei A, Rampini P, Dellabonzana D, Scarduelli C, Spelta B (1982) Treatment of hyperprolactinemic states with different drugs: a study with bromocriptine, metergoline, and lisuride. Fertil Steril 37: 61–67

    PubMed  CAS  Google Scholar 

  • Da Prada M, Bonetti EP, Keller HH (1977) Induction of mounting behaviour in female and male rats by lisuride. Neurosci Lett 6: 349–353

    Article  PubMed  Google Scholar 

  • De Cecco L, Venturini PL, Ragni N, Valenzano M, Constantini S, Horowski R (1983) Dopaminergic ergots in lactation and cycle disturbances. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 291–299

    Google Scholar 

  • Delitala G, Wass JAH, Stubbs WA, Jones A, Williams S, Besser GM (1979) The effect of lisuride hydrogen maleate, an ergot derivative on anterior pituitary hormone secretion in man. Clin. Endocrinol 11: 1–9

    Article  CAS  Google Scholar 

  • Desaga U, Lüdecke D, Kühne D (1983) Prolactin lowering effect of lisuride and reduction of tumor size in patients with prolactinomas. Periodicum Biologorum 85, Suppl 1: 73–82

    Google Scholar 

  • Desaga U, Reich-Schulze E, Gräf K-J, Dorow R, Frahm H (1985) Endocrine effects of the dopamine agonist lisuride in patients with chronic renal failure on long-term hemodialysis. In: MacLeod RM, Thorner MO, Scapagnini U (eds) Prolactin. Basic and clinical correlates. Liviana, Padova, pp 761–771

    Google Scholar 

  • Dorow R, Gräf K-J, Nieuweboer B, Horowski R (1980) Intravenous lisuride: a new tool for testing responsiveness to dopaminergic agonists and neuroendocrine function. Acta Endocrinol (Kbh) 94, Suppl 234: 9 (abstract)

    Google Scholar 

  • Dorow R, Breitkopf M, Desaga U, Ebeling J, Zimmermann R, Horowski R (1981) Pharmacokinetics and clinical effects of lisuride. Acta Endocrinol 97, Suppl 243: 413 (abstract)

    Google Scholar 

  • Dorow R, Breitkopf M, Gräf K-J, Horowski R (1983) Neuroendocrine effects of lisuride and its 9,10-dihydrogenated analog in healthy volunteers. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 161–174

    Google Scholar 

  • Fink H, Morgenstern R (1985) Locomotor effects of lisuride: a consequence of dopaminergic and serotonergic actions. Psychopharmacology 85: 464–468

    Article  PubMed  CAS  Google Scholar 

  • Flosbach CW, Bräutigam M, Dreesen R, Herken H (1982) Action of lisuride on reserpine-induced muscular rigidity in rats after local application into the striatum, ventricular space or the spinal subarachnoid space. Arzneim Forsch Drug Res 32: 488–491

    CAS  Google Scholar 

  • Frattola L, Albizzati MG, Bassi S, Ferrarese C, Trabucchi M (1982) ‘On-Off’ phenomena, dyskinesias and dystonias. Acta Neurol Scand 66:227–236

    Google Scholar 

  • Frattola L, Albizzati MG, Alemani A, Bassi S, Ferrarese C, Trabucchi M (1983) Acute treatment of Huntington’s chorea with lisuride. J Neurol Sci 59: 247–253

    Article  PubMed  CAS  Google Scholar 

  • Fujita N, Saito K, Yonehara N, Watanabe Y, Yoshida H (1979) Binding of [3H] lisuride hydrogen maleate to striatal membranes of rat brain. Life Sci 25: 969–974

    Article  PubMed  CAS  Google Scholar 

  • Fuxe K, Fredholm BB, Ögren S-O, Agnati LF, Hökfelt T, Gustafsson J-A (1978) Ergot drugs and central monoaminergic mechanisms: a histochemical, biochemical and behavioural analysis. Fed Proc 37: 2181–2191

    PubMed  CAS  Google Scholar 

  • Garattini S, Consolo S, Ladinski H (1980) Neuronal links in the CNS: focus on dopaminergic and serotonergic regulation of striatal cholinergic neurons. Pol J Pharmacol Pharm 32:155–164

    PubMed  CAS  Google Scholar 

  • Gerber R, Barbaz BJ, Martin LL, Neale R, Williams M, Liebman JM (1985) Antagonism of L-5-hydroxytryptophan-induced head twitching in rats by lisuride: a mixed 5-hydroxytryptamine agonist-antagonist? Neurosci Lett 60: 207–213

    Article  PubMed  CAS  Google Scholar 

  • Gessa GL (1988) Agonist and antagonist actions of lisuride on dopamine neurons: electrophysiological evidence In: Obeso JA, Horowski R, Marsden CD (eds) Continuous dopaminergic stimulation in Parkinson’s disease. J Neural Transm (Suppl) 27:201–210

    Google Scholar 

  • Giuliani L, Barreca T, Giberti C, Pescatore D, Magnani G, Martorana G, Bottaro L, Damonte P, Rolandi E (1982) Clinical effects of a prolactin-inhibiting drug, lisuride, in patients with benign prostatic hypertrophy. Curr Ther Res 32: 8–16

    Google Scholar 

  • Glusa E, Markwardt F (1984) Mechanism of metallic mercury oxidation in vitro by catalase and peroxidase. Biochem Pharmacol 33: 490–493

    Article  Google Scholar 

  • Glusa E, Markwardt F, Barthel W (1979) Studies on the inhibition of adrenaline-induced aggregation of blood platelets. Pharmacology 19: 196–201

    Article  PubMed  CAS  Google Scholar 

  • Gopinathan G, Teravainen H, Dambrosia J, Ward C, Sanes J, Stuart W, Evarts E, Calne D (1980) Studies on parkinson disease II: evaluation of lisuride as a therapeutic agent. Annu Course of the American Academy of Neurology, 32nd Meeting, New Orleans (abstract)

    Google Scholar 

  • Gopinathan G, Teräväinen H, Dambrosia JM, Ward CD, Sanes JN, Stuart WK, Evarts EV, Calne DB (1981) Lisuride in parkinsonism. Neurology (NY) 31: 371–376

    CAS  Google Scholar 

  • Graf M, Pletscher A (1979) Shape change of blood platelets — a model for cerebral 5-hydroxytryptamine receptors? Br J Pharmacol 65: 601–608

    PubMed  CAS  Google Scholar 

  • Gräf K-J, Neumann F, Horowski R (1976) Effect of the ergot derivative lisuride hydrogen maleate on serum prolactin concentrations in female rats. Endocrinology 98: 598–605

    Article  PubMed  Google Scholar 

  • Gräf K-J, Horowski R, El Etreby MF (1977) Effect of prolactin inhibitory agents on the ectopic anterior pituitary and the mammary gland in rats. Acta Endocrinol. 85: 267–278

    PubMed  Google Scholar 

  • Gräf K-J, Schmidt-Gollwitzer M, Horowski R, Dorow R (1982) Effect of metoclopramide and lisuride on hypophyseal and gonadal function in men. Clin Endocrinol 17: 243–251

    Article  Google Scholar 

  • Halbhübner K, Herken H, Loos D (1978) Experimental neuropathy with parkinsonlike muscular rigidity. Arzneim Forsch Drug Res 28: 1743–1752

    Google Scholar 

  • Hara K, Ikoma Y, Oshino N (1982 a) Effects of an ergot derivative, lisuride, on the central dopaminergic system — studies of behavioral pharmacology. Folia Pharmacol Jp 80: 1–13

    Google Scholar 

  • Hara K, Ikoma Y, Nakao H, Ezumi K, Oshino N, Shiota C, Sasagawa S (1982 b) Central dopaminergic function in stroke-prone spontaneously hypertensive rats (SHRSP): II. Effects of chronic treatment with lisuride on the impaired swimming ability. Folia Pharmacol Jp 80: 385–394

    Google Scholar 

  • Hardie RJ, Lees AJ, Stern GM (1984) On-off fluctuations in Parkinson’s disease: a clinical and neuropharmacological study. Brain 107: 487–506

    Article  PubMed  Google Scholar 

  • Hardt W, Schmidt-Gollwitzer M, Horowski R (1979) Suppression of lactation with lisuride. Gynecol Obstet Invest 10: 95–105

    Article  PubMed  CAS  Google Scholar 

  • Heinlein W, Stracke H, Schroder O, Laube H, Grothe E, Schatz H (1983) Dopaminagonistentherapie bei Hypophysentumoren. Therapiewoche 33: 6123–6128

    Google Scholar 

  • Herrmann WM, Horowski R, Dannehl K, Kramer U, Lurati K (1977) Clinical effectiveness of lisuride hydrogen maleate: a double blind trial versus methysergide. Headache 17: 54–60

    Article  PubMed  CAS  Google Scholar 

  • Herrmann WM, Kristof M, Sastre y Hernandez M (1978) Preventive treatment of migraine headache with a new isoergolenyl derivative. J Int Med Res 6: 476–482

    CAS  Google Scholar 

  • Holohean AM, White FJ, Appel JB (1982) Dopaminergic and serotonergic mediation of the discriminable effects of ergot alkaloids. Eur J Pharmacol 81: 595–601

    Article  PubMed  CAS  Google Scholar 

  • Horowski R (1978) Differences in the dopaminergic effects of the ergot derivatives bromocriptine, lisuride and d-LSD as compared with apomorphine. Eur J Pharmacol 51: 157–166

    Article  PubMed  CAS  Google Scholar 

  • Horowski R ( 1982 a) Role of monoaminergic mechanisms in the mechanism of action of ergot derivatives used in migraine. In: Rose FC (ed) Advances in migraine. Raven, New York, pp 187–198

    Google Scholar 

  • Horowski R (1982 b) Some aspects of the dopaminergic action of ergot derivatives and their role in the treatment of migraine. Adv Neurol 33:325–334

    Google Scholar 

  • Horowski R (1983) Pharmacological effects of lisuride and their potential role in further research. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 127–139

    Google Scholar 

  • Horowski R (1986) Psychiatric side-effects of high-dose lisuride therapy in parkinsonism. Lancet II:510 (letter)

    Article  Google Scholar 

  • Horowski R, Dorow R (1981) Influence of estraciol and other gonadal steroids on central effects of lisuride and comparable ergot derivatives. In: Wuttke W, Horowski R (eds) Gonadal steroids and brain function. Springer, Berlin Heidelberg New York, pp 169–181

    Google Scholar 

  • Horowski R, Gräf K-J (1976) Influence of dopaminergic agonists and antagonists on serum prolactin concentrations in the rat. Neuroendocrinology 22: 273–286

    Article  PubMed  CAS  Google Scholar 

  • Horowski R, McDonald RJ (1983) Experimental and clinical aspects of ergot derivatives used in the treatment of age-related disorders. In: Agnoli A et al. (eds) Aging brain and ergot alkaloids, Raven, New York, Aging 23: 283–303

    Google Scholar 

  • Horowski R, Riedel C (1979) Hypothermic action on lisuride in rats and differences to bromocriptine in the antagonistic effect of neuroleptics. Naunyn-Schmiedeberg’s Arch. Pharmacol. 306: 147–151

    CAS  Google Scholar 

  • Horowski R, Runge I (1986) Possible role of gonadal hormones as triggering factors in migraine. Funct. Neurol. 4: 405–414

    Google Scholar 

  • Horowski R, Wachtel H (1976) Direct dopaminergic action of lisuride hydrogen maleate an ergot derivative in mice. Eur.J. Pharmacol. 36: 373–383

    Article  PubMed  CAS  Google Scholar 

  • Horowski R, Neumann F, Gräf K-J (1975) Influence of apomorphine hydrochloride, dibutyryl-apomorphine and lysenyl on plasma prolactin concentrations in the rat. J Pharm Pharmac 27: 532–534

    Article  CAS  Google Scholar 

  • Horowski R, Wachtel H (1979) Pharmacological effects of lisuride in rodents mediated by dopaminergic receptors: mechanism of action and influence of chronic treatment with lisuride. In: Fuxe K, Calne DB (eds) Dopaminergic ergot derivatives and motor function. Pergamon, Oxford, pp 237–251

    Google Scholar 

  • Horowski R, von Berswordt-Wallrabe R, Gräf K-J (1976) Role of serotoninergic mechanisms in the regulation of prolactin secretion and possible mechanism of action of ergot derivatives. In: Endroczi E (ed) Cellular and molecular bases of neuroendocrine processes. Akadémiai Kiadó, Budapest, pp 183–195

    Google Scholar 

  • Horowski R, Wendt H, Gräf K-J (1977) Inhibition of basal and stimulated prolactin secretion by lisuride in humans, Acta Endocrinol. (Kbh.) 87: 234–240

    Google Scholar 

  • Horowski R, Wachtel H, Dorow R (1986) Dopamine as a deuteragonist in migraine: implications for clinical pharmacology of dopamine agonists. In: Winlow W, Markstein R (eds) The neurobiology of dopamine systems. Manchester University Press, Manchester, pp 415–426

    Google Scholar 

  • Hümpel M (1983) Pharmacokinetics of lisuride in animals species and humans. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 411–152

    Google Scholar 

  • Hümpel M, Nieuweboer B, Hasan SH, Wendt H (1981) Radioimmunoassay of plasma lisuride in man following intravenous and oral administration of lisuride hydrogen maleate; effects on plasma prolactin level. Eur J Clin Pharmacol 20: 47–51

    Article  PubMed  Google Scholar 

  • Itil TM, Herrmann M, Akpinar S (1974) Lisuride hydrogen maleate, a new psychotropic, discovered by quantitative pharmaco-electroencephalogram. Int J Clin Pharmacol 10: 143 (Abstract)

    Google Scholar 

  • Itil TM, Akpinar S, Herrmann W (1975) Discovery of specific ens effects of lisuride hydrogen maleate — an antimigraine compound. Psychopharmacol Bull 11: 67

    PubMed  CAS  Google Scholar 

  • Jackson DM, Jenkins OF (1985) Hypothesis: bromocriptine lacks intrinsic dopamine receptor stimulating properties. J Neural Transm 62: 219–230

    Article  PubMed  CAS  Google Scholar 

  • Johnson AM, Loew DM, Vigouret JM (1976) Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and L-dopa. Br J Pharmac 56: 59

    CAS  Google Scholar 

  • Kebabian JW, Kebabian PR (1978) Lergotrile and lisuride: in vivo dopaminergic agonists which do not stimulate the presynaptic dopamine autoreceptor. Life Sci 23: 2199–2204

    Article  PubMed  CAS  Google Scholar 

  • Kehr W (1977) Effect of lisuride and other ergot derivatives on mono-aminergic mechanisms in rat brain. Eur J Pharmacol 41: 261–273

    Article  PubMed  CAS  Google Scholar 

  • Kehr W, Speckenbach W (1978) Effect of lisuride and LSD on monoamine synthesis after axotomy or reserpine treatment in rat brain. Naunyn-Schmiedeberg’s Arch Pharmacol 301: 163–169

    Article  PubMed  CAS  Google Scholar 

  • Keller HH, Da Prada M (1979) Central dopamine agonistic activity and microsomal biotransformation of lisuride, lergotrile and bromocriptine. Life Sci 24: 1211–1222

    Article  PubMed  CAS  Google Scholar 

  • Krause W, Nieuweboer B, Ruggieri St, Stocchi F, Suchy I (1988) Pharmacokinetics of lisuride after subcutaneous infusion. In: Obeso JA, Horowski R, Marsden CD (eds) Continuous dopaminergic stimulation in Parkinson’s disease. J Neural Trans (Suppl) 27: 71–74

    Google Scholar 

  • Krejci I, Schuh J, Pragerova H, Dlabac A (1985) Lisuride and transdihydrolisuride: differences in action on central dopaminergic function in dependence on the location and the state of receptors. Pol J Pharmacol Pharm 37: 263–272

    PubMed  CAS  Google Scholar 

  • Ladinsky H (1977) Effect of lisuride on the central cholinergic system. In: Istituto di Ricerche Farmacologiche ‘Mario Negri’, Milan, pp 5–18

    Google Scholar 

  • Laihinen A, Rinne UK, Sonninen V, Suchy I (1986) Lisuride in comparison to bromocriptine in the treatment of Parkinson’s disease. 26th Scandinavian Congress of Neurology, Uppsala, June 11–14, 1986, Uppsala, J Med Sci Suppl 43: 92

    Google Scholar 

  • Lamberti P, Bandiera L, De Liso E, Demari M, Fiore P, Iliceto G, Margari L (1986) Rilievi clinici, neuropsicologici e neurofisiologici in Parkinsoniani trattati con lisuride. In: Agnoli A, Battistin L (eds) L.I.M.P.E., Atti della 12. Riunione Morbo di Parkinson: le nuove terapie. Guanella, Rome, pp 197–206

    Google Scholar 

  • Lees AJ, Bannister R (1981) The use of lisuride in the treatment of multiple system atrophy with autonomie failure (Shy-Drager syndrome). J Neurol Neurosurg Psychiat 44: 347–351

    Article  PubMed  CAS  Google Scholar 

  • Lees AJ, Bannister R (1983) Treatment of the Shy-Drager syndrome with dopaminergic ergots. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 395–405

    Google Scholar 

  • Lees AJ, Stern GM (1981) Pergolide and lisuride for levodopa-induced oscillations. Lancet II: 577

    Google Scholar 

  • Leiguarda R, Micheli F, Fernandez Pardal M (1985) Lisuride en la enfermedad de Parkinson. Medicina (Buenos Aires) 45: 29–34

    CAS  Google Scholar 

  • LeWitt PA (1986) Clinical and pharmacological aspects of the antiparkisonian ergolene lisuride. In: Fahn S et al. (eds) Recent developments in Parkinson’s disease. Raven, New York, pp 347–354

    Google Scholar 

  • LeWitt PA, Gopinathan G, Ward CD, Sanes JN, Dambrosia JM, Durso R, Calne DB (1982) Lisuride versus bromocriptine treatment in Parkinson disease: a double- blind study. Neurology (Ny) 32: 69–72

    CAS  Google Scholar 

  • Lieberman AN, Leibowitz M, Neophytides A, Kupersmith M, Mehl S, Kleinberg D, Serby M, Goldstein M (1979) Pergolide and lisuride for Parkinson’s disease. Lancet II/8152:1129–1130

    Article  Google Scholar 

  • Lieberman A, Neophytides A, Leibowitz M, Kupersmith M, Pact V, Walker R, Zarosin N, Goodgold A, Goldstein M (1980) The use of two new dopamine agonists: pergolide and lisuride in Parkinson’s disease. In: Rinne UK, Klinger M, Stamm G (eds) Parkinson’s disease - current progress, problems and management. Elsevier/ North Holland Biomedical, Amsterdam, pp 335–356

    Google Scholar 

  • Lieberman A, Goldstein M, Neophytides A, Kupersmith M, Leibowitz M, Zasorin N, Walker R, Kleinberg D (1981a) Lisuride in parkinson disease: Efficacy of lisuride compared to levodopa Neurology (Ny) 31: 961–965

    CAS  Google Scholar 

  • Lieberman AN, Goldstein M, Leibowitz M, Neophytides A, Gopinathan G, Walker R, Pact V (1981b) Lisuride combined with levodopa in advanced parkinson disease. Neurology (Ny) 31: 1466–1469

    CAS  Google Scholar 

  • Lieberman AN, Goldstein M, Neophytides A, Leibowitz M, Gopinathan G, Goodgold A, Pact V, Walker R (1981 c) Use of lisuride in advanced Parkinson’s disease. N Y State J Medicine Nov 81: 1751–1755

    Google Scholar 

  • Lieberman AN, Goldstein M, Gopinathan G, Leibowitz M, Neophytides A, Walker R, Hiesiger E (1983 a) Further studies with lisuride in Parkinson’s disease. Eur Neurol 22: 119–123

    Google Scholar 

  • Lieberman AN, Goldstein M, Gopinathan G, Neophytides A, Leibowitz M, Walker R, Hiesiger E ( 1983 b) Lisuride in Parkinson’s disease and related disorders. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 419–429

    Google Scholar 

  • Lieberman AN, Gopinathan G, Neophytides A, Leibowitz M, Goldstein M (1984) Pergolide and lisuride in advanced Parkinson’s disease. Adv Neurol 40: 503–507

    PubMed  CAS  Google Scholar 

  • Liuzzi A, Dallabonzana D, Oppizzi G, Verde GG, Cozzi R, Chiodini P, Luccarelli G (1985) Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N Engl J Med 313: 656–659

    Article  PubMed  CAS  Google Scholar 

  • Loew DM, Van Deusen EB, Meier-Ruge W (1978) Effects on the central nervous system. In: Berde B, Schild HO (eds) Ergot alkaloids and related compounds. Springer, Berlin Heidelberg New York, pp 421–531

    Google Scholar 

  • Loos D, Halbhübner K, Herken H (1977) Lisuride, a potent drug in the treatment of muscular rigidity in rats, Naunyn-Schmiedeberg’s Arch Pharmacol 300: 195–198

    Article  CAS  Google Scholar 

  • Loos D, Halbhübner K, Kehr W, Herken H (1979) Action of dopamine agonists on parkinson-like muscle rigidity induced by 6-aminonicotinamide. Neuroscience 4: 667–676

    Article  PubMed  CAS  Google Scholar 

  • Lüdecke DK, Herrmann, H-D, Hörmann C, Desaga U, Saeger W (1983) Comparison of effects of dopamine agonists and microsurgery in GH- and PRL-secreting adenomas. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 271–289

    Google Scholar 

  • Luquin MR, Obeso JA, Martinez-Lage JM, Tresguerres J, Parada J, Nieuweboer B, Dorow R, Horowski R (1986) Parenteral administration of lisuride in Parkinson’s disease. In: Adv Neurol 45: 561–568

    Google Scholar 

  • MacLeod RM (1977) Influence of dopamine, serotonin, and their antagonists on prolactin secretion. Prog Reprod Biol 2: 54–68

    CAS  Google Scholar 

  • Mannesmann G, Haberey M, Müller B, Goedecke H (1979) Pharmacological characterization of the cardiovascular activity of lisuridhydrogenmaleate. Naunyn- Schmiedeberg’ Arch. Pharmacol. Suppl 308: 72 (abstract)

    Google Scholar 

  • Marek J, Rezábek K, Srámková (1982) Medikamentöse Behandlung der Hyperprolaktinämie, Akromegalie und Cushing-Krankheit. Ber Ges Inn Med 13: 246–248

    Google Scholar 

  • Marini JL, Sheard MH (1981) On the specificity of a cat behavior model for the study of hallucinogens. Eur J Pharmacol 70: 479–487

    Article  PubMed  CAS  Google Scholar 

  • Marini JL, Jacobs BL, Sheard MH, Trulson ME (1981) Activity of a non-halluciongenic ergoline derivative, lisuride, in an animal behavior model for hallucinogens. Psychopharmacology 73: 328–331

    Article  PubMed  CAS  Google Scholar 

  • Martignoni E, Suchy I, Pacchetti C, Sinforiani E, Sandrini G, Nappi G (1986) Lisuride in Parkinson’s disease: naive and long-term treatment. Curr Ther Res 39: 696–708

    Google Scholar 

  • McCall RB (1982) Neurophysiological effects of hallucinogens on serotonergic neuronal systems. Neurosci Biobehav Rev 6: 509–514

    Article  PubMed  CAS  Google Scholar 

  • McCall RB, Aghajanian GK (1980) Hallucinogens potentiate responses to serotonin and norepinephrine in the facial motor nucleus. Life Sci 26: 1149–1156

    Article  PubMed  CAS  Google Scholar 

  • McCall RB, Humphrey SJ (1982) Involvement of serotonin in the central regulation of blood pressure: Evidence for a facilitating effect on sympathetic nerve activity. J Pharm Exp Ther 222: 94–102

    CAS  Google Scholar 

  • McDonald RJ, Horowski R (1983) Lisuride in the treatment of parkinsonism. Eur Neurol 22: 240–255

    Article  PubMed  CAS  Google Scholar 

  • McPherson GA, Beart PM (1983) The selectivity of some ergot derivatives for alpha-1-and alpha-2-adrenoceptors of rat cerebral cortex. Eur J Pharmacol 91: 363–369

    Article  PubMed  CAS  Google Scholar 

  • Mereu G, Muntoni F, Collu M, Boi V, Gessa GL (1986) Delayed blockade of dopamine autoreceptors by lisuride In: Biggio S, Spano FP, Toffano G, Gessa GL (eds) Modulation of central and peripheral transmitter function. Liviana/Springer, Berlin Heidelberg New York, pp 597–601

    Google Scholar 

  • Mereu G, Hu XT, Wang RY, Westfall TC, Gessa GL (1987) Failure of subchronic lisuride to modify A10 dopamine autoreceptors’ sensitivity. Brain Res 408: 210–214

    Article  PubMed  CAS  Google Scholar 

  • Micheli F, Fernandez Pardal MM, Leiguarda RC (1982) Beneficial effects of lisuride in Meige disease. Neurology (Ny) 32: 432–434

    CAS  Google Scholar 

  • Misurek J, Morávek Z, Náhunek K (1978) Lisurid (Lysenyl SPOFA) in the treatment of organic psychosyndrome in involution, Activ Nerv Sup (Praha) 20: 87–88

    Google Scholar 

  • Munemara M, Eskay RL, Kebabian JW, Long R (1980) Release of alpha-melanocytestimulating hormone from dispersed cells of the intermediate lobe of the rat pituitary gland: involvement of catecholamines and adenosine 3′,5′-monophosphate, Endocrinology 106: 1795–1803

    Article  Google Scholar 

  • Neophytides A, Lieberman AN, Goldstein M, Gopinathan G, Leibowitz M, Bock J, Walker R (1982) The use of lisuride, a potent dopamine and serotonin agonist, in the treatment of progressive supranuclear palsy. J Neurol Neurosurg Psychiat 45: 261–263

    Article  PubMed  CAS  Google Scholar 

  • Nutt JG, Hammerstad JP, Carter JH, DeGarmo PL (1984) Lisuride treatment of cranial dystonia. 36th Meeting of the American Academy of Neurology, Boston, April 1984

    Google Scholar 

  • Obeso JA (1984) Untersuchung und Behandlung des Myoclonus. Akt. Neurol. 11: 210–213

    Article  Google Scholar 

  • Obeso JA, Rothwell JC, Quinn NP, Lang AE, Thompson C, Marsden CD (1983) Cortical reflex myoclonus responds to intravenous lisuride, Clin Neuropharmacol 6: 231–240

    Article  PubMed  CAS  Google Scholar 

  • Obeso JA, Luquin MR, Martinez Lage JM (1985) Lisuride oral en la enfermedad de Parkinson. Medicina Clinica (Barcelona) 85: 307–312

    CAS  Google Scholar 

  • Obeso JA, Luquin MR, Martinez-Lage JM (1986) Lisuride infusion pump: a device for the treatment of motor fluctuations in Parkinson’s disease. Lancet 1: 467–470

    Article  PubMed  CAS  Google Scholar 

  • Obeso JA, Horowski R, Marsden CD (eds) (1988) Continuous Dopaminergic Stimulation in Parkinson’s disease. J Neural Transm (Suppl) 27

    Google Scholar 

  • Otomo E, Hasegawa K, Kuroiwa Y et al. (1981) Effects of lisuride hydrogen maleate on EEG in patients with cerebral vascular impairments and mild senile dementia: multicenter double-blind study, Jpn J Clin Pharmacol Ther 12: 377–396

    Article  Google Scholar 

  • Parkes JD, Schachter M, Marsden CD, Smith B, Wilson A (1981) Lisuride in parkinsonism, Ann Neurol 9: 48–52

    Article  PubMed  CAS  Google Scholar 

  • Pieri L, Keller HH, Burkard W, Da Prada M (1978) Effects of lisuride and LSD on cerebral monoamine systems and hallucinosis, Nature 272: 278–280

    Article  PubMed  CAS  Google Scholar 

  • Pieri L, Keller HH, Laurent J-P, Burkard WP, Pieri M, Bonetti EP, Da Prada M (1983) Behavioral, neurochemical, and electrophysiological effects of lisuride and LSD in animals. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 89–96

    Google Scholar 

  • Podvalovà I, Dlabac A (1972) Lysenyl, a new antiserotonin agent. Res Clin Stud Headache 3: 325–334

    Google Scholar 

  • Quinn NP (1984) Antiparkinsonian drugs today, Drugs 28: 236–262

    Article  PubMed  CAS  Google Scholar 

  • Quinn N, Marsden CD, Schachter M, Thompson C, Lang AE, Parkes JD (1983) Intravenous lisuride in extrapyramidal disorders. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 383–393

    Google Scholar 

  • Quinn N, Parkes JD, Marsden CD (1984) Control of on/off phenomenon by continuous intravenous infusion of levodopa. Neurology 34: 1131–1136

    PubMed  CAS  Google Scholar 

  • Quinn NP, Lang AE, Sheehy MP, Marsden CD (1985) Lisuride in dystonia. Neurology 35: 766–769

    PubMed  CAS  Google Scholar 

  • Rabey JM, Treves T, Streifler M, Korczyn AD (1986) Comparison of efficacy of lisuride hydrogen maleate with increased doses of levodopa in parkinsonian patients. Adv Neurol 45: 569–572

    Google Scholar 

  • Rabey JM, Streifler M, Treves T, Korczyn AD (1987) Long-term lisuride in Parkinson’s disease. In: Calne DB, Crippa D, Comi G (eds) Int symp parkinsonism and aging, suppl 7. Ital J Neurol Sci Suppl 5: 55

    Google Scholar 

  • Raffaelli E, Martins OJ, dos Santos P, Dàgua Filho A (1983) Lisuride in cluster headache. Headache 23: 117–121

    Article  PubMed  Google Scholar 

  • Reynolds GP, Riederer P (1981) The effects of lisuride and some other dopaminergic agonists on receptor binding in human brain. J Neural Transm 51: 107–111

    Article  PubMed  CAS  Google Scholar 

  • Riederer P, Reynolds GP, Danielczyk W, Jellinger K, Seemann D (1983) Desensitization of striatal spiperone-binding sites by dopaminergic agonists in Parkinson’s disease. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 375–381

    Google Scholar 

  • Rinne UK (1983) New ergot derivatives in the treatment of Parkinson’s disease. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 431–442

    Google Scholar 

  • Rinne UK (1986) The importance of an early combination of a dopamine agonist and levodopa in the treatment of Parkinson’s disease. In: van Manen J, Rinne UK (eds) Lisuride: a new dopamine agonist and Parkinson’s disease. Excerpta Medica, Amsterdam, pp 64–71

    Google Scholar 

  • Ripka O (1972) Effetti della soministrazione a lungo termine dell’ anti-serotoninico lysenyl nelle cefalee di varia eziologia. Minerva Med 63: 3266–3271

    PubMed  CAS  Google Scholar 

  • Rogawski MA, Aghajanian GK (1979) Response of central monaminergic neurons to lisuride: comparison with LSD, Life Sci 24: 1289–1298

    Article  PubMed  CAS  Google Scholar 

  • Rosenfeld MR, Makman MH (1981) The interaction of lisuride, an ergot derivative, with serotonergic and dopaminergic receptors in rabbit brain. J Pharmacol Exp Ther 216: 526–531

    PubMed  CAS  Google Scholar 

  • Rosenfeld MR, Makman MH, Goldstein M (1980) Stimulation of adenylate cyclase in rat striatum by pergolide: influence of GTP. Eur J Pharmacol 68: 65–68

    Article  PubMed  CAS  Google Scholar 

  • Rothwell JC, Obeso JA, Marsden CD (1984) On the significance of giant somatosensory evoked potentials in cortical myoclonus. J Neurol Neurosurg Psychiat 47: 33–42

    Article  PubMed  CAS  Google Scholar 

  • Ruggieri S, Baldassarre M, Del Roscio S, Stocchi F, Palesse N, Martucci N, Agnoli A (1980) Confronto tra l’attività terapeutica della lisuride e della bromocriptina nel morbo di Parkinson. In: Atti della 7. Riunione. LIMPE, Milan 24–25 Oct 1980

    Google Scholar 

  • Ruggieri S, Stocchi F,Agnoli A (1986) Lisuride infusion pump for Parkinson’s disease, Lancet 11:348–349 (letter)

    Google Scholar 

  • Ruggieri S, Stocchi F, Antonini A, Bellantuono P, Carta A, Agnoli A (1987) Lisuride infusion in chronically treated fluctuating Parkinson’s disease: effects of continuous dopaminergic stimulation, New Trends Clin Neuropharmacol 1: 55–60

    Google Scholar 

  • Ruilope L, Garcia-Robles R, Paya C, de Villa LF, Miranda B, Morales JM, Parada J, Sancho J, Rodicio JL (1985) Influence of lisuride, a dopaminergic agonist, on the sexual function of male patients with chronic renal failure. Am J Kidney Dis 5: 182–185

    CAS  Google Scholar 

  • Saiani L, Trabucchi M,Tonon GC, Spano PF (1979) Bromocriptine and lisuride stimulate the accumulation of cyclic AMP in intact slices but not in homogenates of rat neostriatum. Neurosci Lett 14: 31–36

    PubMed  CAS  Google Scholar 

  • Scaglioni A, Caffarra P, Passeri S, Saginario M (1986) Trattamento a lungo termine con lisuride nel morbo di Parkinson, In: Agnoli A, Battistin L (eds) LIMPE, Atti della 12. Riunione ‘Morbo di Parkinson: le nuove terapie’. Guanella, Rome, pp 207–217

    Google Scholar 

  • Schachter M, Blackstock J, Dick JPR, George RJD, Marsden CD, Parkes JD (1979) Lisuride in Parkinson’s disease. Lancet 11/8152:1129

    Google Scholar 

  • Schachter M, Sheehy MP, Parkes JP, Marsden CD (1980) Lisuride in the treatment of parkinsonism, Acta Neurol Scand 32: 382–385

    Google Scholar 

  • Schmidt-Gollwitzer M, Hardt W, Schmidt-Gollwitzer K, Nevinny-Stickel J (1977) Vergleichsstudie über den Einfluß verschiedener Sexual-steroide, 2-Br-Alpha-Ergokryptin und Lisurid-hydrogenmaleat auf die postpartalen Prolaktin-Serumkonzentrationen und die Laktation. Geburtsh Frauenheilk 37: 500–508

    PubMed  CAS  Google Scholar 

  • Schneider WHF (1983) Lisuride and female fertility. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 331–335

    Google Scholar 

  • Scholz A, Horowski R (1987) Effects of the prolactin-lowering agent lisuride (Dopergin R) in early pregnancy. In: Teoh ES, Ratnam SS, Wong PC (eds) Ovulation and early pregnancy. Parthenon, Carnforth, pp 159–162

    Google Scholar 

  • Schorderet M (1978) Dopamine-mimetic activity of cyclic AMP in isolated retinae of the rabbit. Gerontology 24, Suppl 1: 86–93

    Google Scholar 

  • Schwibbe M, Becker D, Wuttke W (1983) EEG and psychological effects of lisuride in women with premenstrual tension. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 345–355

    Google Scholar 

  • Scigliano G, Giovannini P, Grassi MP, Soliveri P, Parati E, Mallucci C, Caraceni T (1982) La lisuride nel trattamento del morbo di Parkinson. In: Atti della 9. Riunione LIMPE, Taormina, 29–30 Oct 1982

    Google Scholar 

  • Scigliano G, Giovannini P, Grassi MP, Soliveri P, Piccolo I, Lamperti E, Girotti F, Caraceni T (1985) Valutazione dell’efficacia a lungo termine della lisuride nel trattamento del morbo di Parkinson. In: Agnoli A, Battistin L (eds) LIMPE, Atti della 11. Riunione ‘Semeiologia e terapia: delle malattie extrapiramidali le nuove frontiere.’ Guanella, Rome, pp 250–262

    Google Scholar 

  • Shoulson I, Glaubiger GA, Chase TN (1975) On-off response: clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 25: 1144–1148

    PubMed  CAS  Google Scholar 

  • Silbergeld EK, Hruska RE (1979) Lisuride and LSD: dopaminergic and serotonergic interactions in the „serotonin syndrome“. Psychopharmacology 65: 233–237

    Article  PubMed  CAS  Google Scholar 

  • Somerville BW, Herrmann WM (1978) Migraine prophylaxis with lisuride hydrogen maleate — a double blind study of lisuride versus placebo. Headache 18: 75–79

    Article  PubMed  CAS  Google Scholar 

  • Spano PF, Govoni S, Trabucchi M (1978) Studies on the pharmacological properties of dopamine receptors in various areas of the central nervous system In: Adv Biochem Psychopharmacol 19: 155–165

    Google Scholar 

  • Spano PF, Saiani L, Memo M, Trabucchi M (1980) Interaction of dopaminergic ergot derivatives with cyclic nucleotide system. In: Goldstein M et al. (eds) Ergot compounds and brain function: Neuroendocrine and neuropsychiatric aspects. Raven, New York, pp 95–102

    Google Scholar 

  • Spano PF, Govoni S, Uzumaki H, Bosio A, Memo M, Lucchi L, Carruba M, Trabucchi M (1983) Stimulation of D2-dopamine receptors by dopaminergic ergot alkaloids: studies on the mechanism of action. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 165–117

    Google Scholar 

  • Stibe CMH, Lees AJ, Kempster PA, Stern GM (1988) Subcutaneous apomorphine in parkinsonian on-off oscillations, Lancet 1: 403–406

    Article  PubMed  CAS  Google Scholar 

  • Stocchi F, Ruggieri S, Brughitta G, Agnoli A (1986) Problems in daily motor performances in Parkinson’s disease: the continuous dopaminergic stimulation. J Neural Transm 22: 209–218

    CAS  Google Scholar 

  • Stumpf WE, Detmer WM, Sar M, Horowski R, Dorow R (1985) Autoradiographic studies with [3H] dopamine, and [3H] domperidone in pituitary and brain. In: Macleod RM, Thorner MO, Scapagnini U (eds) Prolactin. Basic and clinical correlates, Liviana, Padova, pp 27–35

    Google Scholar 

  • Suchy I (1986) Neurotransmitters in intellectual deterioration and dementia in presenium and senium. In: van Manen J, Rinne UK (eds) Lisuride: a new dopamine agonist and Parkinson’s disease. Excerpta Medica, Amsterdam, pp 38–43

    Google Scholar 

  • Suchy I, Horowski R (1984) Use of ergot derivative lisuride in Parkinson’s disease. In: Adv Neurol 40: pp 515–521

    Google Scholar 

  • Suchy I, Schneider HH, Riederer P, Horowski R (1983) Considerations on the clinical relevance of differences in receptor affinity of various dopaminergic ergot alkaloids. Psychopharmacol. Bull. 19: 743–746

    CAS  Google Scholar 

  • Thorner MO, Vance ML, MacLeod RM (1984) Hyperprolactinaemic infertility: some considerations on medical management. In: Rolland R (ed) Advances in fertility control and the treatment of sterility. MTP Press, Boston, pp 23–25

    Google Scholar 

  • Tissari AH, Gessa GL (1983) Ergot-induced inhibition of dopamine synthesis in striatal synaptosomes: A D-2 DA receptor-mediated mechanism. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 33–43

    Google Scholar 

  • Tissari AH, Rossetti ZL, Meloni M, Frau MI, Gessa Gl (1983) Autoreceptors mediate the inhibition of dopamine synthesis by bromocriptine and lisuride in rats. Eur J Pharmacol 91: 463–468

    Article  PubMed  CAS  Google Scholar 

  • Ulm G (1983) Experience with lisuride in the treatment of Parkinson’s disease. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists.

    Google Scholar 

  • Raven, New York, pp 463–472

    Google Scholar 

  • Ulm G, Suchy I (1986) Drug treatment of Parkinson’s disease with special reference to lisuride. In: van Manen J, Rinne UK (eds) Lisuride: a new dopamine agonist and Parkinson’s disease. Excerpta Medica, Amsterdam, pp 55–63

    Google Scholar 

  • Uzumaki H, Govoni S, Memo M, Carruba MO, Trabucchi M, Spano PF (1982) Effects of GTP and sodium on rat striatal dopamine receptors labeled with lisuride. Brain Res. 248: 185–187

    Article  PubMed  CAS  Google Scholar 

  • van Dam LJ, Rolland R (1981) Lactation-inhibiting and prolactin-lowering effect of lisuride and bromocriptine: a comparative study. Eur J Obstet Gynec Reprod Biol 12: 323–330

    Article  Google Scholar 

  • Venturini PL, Horowski R, Maganza C, Morano S, Pedretti E, Ragni N, Semino F, De Cecco L (1981) Effects of lisuride and bromocriptine on inhibition of lactation and on serum prolactin levels: comparative double-blind study. Eur J Obstet Gynec Reprod Biol 11: 395–400

    Article  CAS  Google Scholar 

  • Verde G, Chiodini PG, Liuzzi A, Cozzi R, Favales F, Botalla L, Spelta B, Dalla Bonzana D, Rainer E, Horowski R (1980) Effectiveness of the dopamine agonist lisuride in the treatment of acromegaly and pathological hyperprolactinemic states. J Endocrinol Invest 4: 405–414

    Google Scholar 

  • Votava Z, Podvalova I, Vojtechovsky M (1966) Unterschiede in der pharmakologischen Wirkung von halluzinogenen und nicht halluzinogenen Lysergsäure-Derivaten (LSD-25, Deseril, Lysenyl, Mesenyl). Arzneim Forsch Drug Res 16: 220–222

    CAS  Google Scholar 

  • Wachtel H (1978) Inhibition of locomotor activity of rats by low doses of different dopamine (DA) receptor agonists. Naunyn-Schmiedeberg’s Arch Pharmacol 302 (Suppl): R 59 (abstract)

    Google Scholar 

  • Wachtel H, Kehr W, Schlangen M (1986) Involvement of dopamine auto- and postsynaptic receptors in locomotor effects of lisuride in rats after systemic or intracerebral administration. In: van Manen J, Rinne UK (eds) Lisuride: a new dopamine agonist and Parkinson’s disease. Excerpta Medica, Amsterdam, pp 11–23

    Google Scholar 

  • Wachtel H, Rettig KJ, Löschmann PA (1988) Effect of chronic subcutaneous mini-pump infusion of lisuride upon locomotor activity in rats. In: Obeso JA, Horowski R, Marsden CD (eds) Continuous dopaminergic stimulation in Parkinson’s disease. J Neural Transm (Suppl) 27: 177–183

    Google Scholar 

  • Walters JR, Baring MD, Lakoski JM (1978) Effects of dopamine agonists on dopaminergic unit activity. In: Usdin E, Kopin IJ, Barchas J (eds) Catecholamines: basic and clinical effects, vol 1. Pergamon, New York, pp 637–639

    Google Scholar 

  • Walters JR, Baring MD, Lakoski JM (1979) Effects of ergolines on dopaminergic and serotonergic single unit activity In: Fuxe K, Calne DB (eds) Dopaminergic ergot derivatives and motor function. Pergamon, Oxford, pp 207–221

    Google Scholar 

  • von Werder K, Fahlbusch R, Rjosk H-K (1983) Dopamine agonists and prolactinomas: clinical and therapeutic aspects In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 255–269

    Google Scholar 

  • White FJ (1986) Comparative effects of LSD and lisuride: clues to specific hallucinogenic drug actions, Pharmacol Biochem Behav 24:365–379

    Article  PubMed  CAS  Google Scholar 

  • White FJ, Wang RY (1982a)Lysergic acid diethylamide (LSD) and lisuride: differentiation of their neuropharmacological actions Science 216: 535–537

    Article  PubMed  CAS  Google Scholar 

  • White FJ, Appel JB (1982 b) The role of dopamine and serotonin in the discriminative stimulus effects of lisuride, J Pharmacol Exp Ther 221: 421–427

    Google Scholar 

  • White FJ, Wang RY (1983) Comparison of the effects of LSD and lisuride on A10 dopamine neurons in the rat. Neuropharmacology 22: 669–676

    Article  PubMed  CAS  Google Scholar 

  • Winkelmann W, Allolio B, Deuß U, Heesen D, Kaulen D, Wilcke O (1983) Medikamentöse Langzeittherapie bei Patienten mit Prolaktin-produzierenden Hypophysentumoren. Akt Endokr Stoffw 4: 163–168

    Google Scholar 

  • Zikán V, Semonsky M (1968) Mutterkorn-Alkaloide: 31. Mitt.: Ein Beitrag zur Herstellung von N-(D-6-Methyl-8-isoergolenyl)-N’N’-diäthylharnstoff. Pharmazie 23: 147–148

    Google Scholar 

Download references

Authors
  1. G. Gopinathan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Horowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I. H. Suchy
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Neurology, UBC Health Sciences Centre Hospital, 2211 Wesbrook Mall, Vancouver, British Columbia, Canada, V6T 1W5

    Donald B. Calne Professor D.M., F.R.C.P., F.R.C.P.C. (Head) (Head)

Rights and permissions

Reprints and permissions

Copyright information

© 1989 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Gopinathan, G., Horowski, R., Suchy, I.H. (1989). Lisuride Pharmacology and Treatment of Parkinson’s Disease. In: Calne, D.B. (eds) Drugs for the Treatment of Parkinson’s Disease. Handbook of Experimental Pharmacology, vol 88. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73899-9_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-73899-9_19

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-73901-9

  • Online ISBN: 978-3-642-73899-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation